Elvina Almuradova· @Dr_ElvinaA · X·· 21 小时前评分70
正文 · 机器翻译
#FLAURA2：早期 ctDNA 清除未能确定哪些患者可以免接受化疗——无论第 1–2 周是否清除，PFS 均倾向于支持 osimertinib 联合化疗。清除率相近，结局却不同。探索性发现，但具有临床相关性！ #ESMO26 @Larvol @myESMO @OncoAlert
10 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
2719RO按 Rapid oral 1: NSCLC, metastatic 对上
FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem)
https://esmocongress.esmo.orgLBA73按 Rapid oral 1: NSCLC, metastatic 对上
PACE-LUNG: A multicenter, single-arm, phase II clinical trial evaluating the efficacy of additional chemotherapy for patients with EGFRm NSCLC with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line
https://esmocongress.esmo.org来源：Elvina Almuradova · x.com